Tvardi Therapeutics (LTS:0HTC) Notes Receivable: £0.00 Mil (As of Mar. 2026)


What is Tvardi Therapeutics Notes Receivable?

Tvardi Therapeutics LTS:0HTC 12 Notes Receivable is £0.00 Mil as of Mar. 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Tvardi Therapeutics's Notes Receivable for the quarter that ended in Mar. 2026 was £0.00 Mil.

Tvardi Therapeutics Notes Receivable Related Terms

Tvardi Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics Notes Receivable Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00 0.00

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Tvardi Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of £0.00 Mil mean?
Tvardi Therapeutics (LTS:0HTC) has a Notes Receivable of £0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Tvardi Therapeutics and its competitors.
Is Tvardi Therapeutics' Notes Receivable too high?
Tvardi Therapeutics' current Notes Receivable is £0.00 Mil. Overall, Tvardi Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Notes Receivable compare to HOWL and TPST?
Tvardi Therapeutics' Notes Receivable of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Tvardi Therapeutics and its competitors. Tvardi Therapeutics's current Notes Receivable is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current Notes Receivable of £0.00 Mil. The current Notes Receivable is £0.00 Mil. Tvardi Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current Notes Receivable is £0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA69C:Germany
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.